DK1305286T3 - Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling - Google Patents

Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling

Info

Publication number
DK1305286T3
DK1305286T3 DK01955162T DK01955162T DK1305286T3 DK 1305286 T3 DK1305286 T3 DK 1305286T3 DK 01955162 T DK01955162 T DK 01955162T DK 01955162 T DK01955162 T DK 01955162T DK 1305286 T3 DK1305286 T3 DK 1305286T3
Authority
DK
Denmark
Prior art keywords
treatment
cyclopentanoindoles
compounds
methods
preparations containing
Prior art date
Application number
DK01955162T
Other languages
Danish (da)
English (en)
Inventor
Marc Labelle
Claudio Sturino
Carl Berthelette
Nicolas Lachance
John Scheigetz
Bruno Roy
Michael Boyd
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of DK1305286T3 publication Critical patent/DK1305286T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal
DK01955162T 2000-07-25 2001-07-23 Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling DK1305286T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (1)

Publication Number Publication Date
DK1305286T3 true DK1305286T3 (da) 2005-03-14

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01955162T DK1305286T3 (da) 2000-07-25 2001-07-23 Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling

Country Status (34)

Country Link
US (1) US6410583B1 (hr)
EP (1) EP1305286B1 (hr)
JP (1) JP4119745B2 (hr)
KR (1) KR100746814B1 (hr)
CN (1) CN1214007C (hr)
AT (1) ATE284388T1 (hr)
AU (2) AU7743001A (hr)
BG (1) BG66084B1 (hr)
BR (1) BR0112756A (hr)
CA (1) CA2416867C (hr)
CZ (1) CZ2003236A3 (hr)
DE (1) DE60107687T2 (hr)
DK (1) DK1305286T3 (hr)
DZ (1) DZ3402A1 (hr)
EA (1) EA006765B1 (hr)
EC (1) ECSP034428A (hr)
EE (1) EE05287B1 (hr)
ES (1) ES2231526T3 (hr)
GE (1) GEP20053595B (hr)
HK (1) HK1058934A1 (hr)
HR (1) HRP20021039B1 (hr)
HU (1) HUP0301745A3 (hr)
IL (2) IL153406A0 (hr)
IS (1) IS2170B (hr)
MX (1) MXPA03000710A (hr)
NO (1) NO325011B1 (hr)
NZ (1) NZ523106A (hr)
PL (1) PL207342B1 (hr)
PT (1) PT1305286E (hr)
RS (1) RS50491B (hr)
SK (1) SK287507B6 (hr)
UA (1) UA73787C2 (hr)
WO (1) WO2002008186A2 (hr)
ZA (1) ZA200300554B (hr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US7141563B2 (en) 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6916922B2 (en) 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
EP1330457B1 (en) * 2000-11-03 2004-10-20 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indoles as 5ht2c antagonists
US6784172B2 (en) 2000-11-03 2004-08-31 Wyeth Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
AU2004240705A1 (en) * 2003-05-20 2004-12-02 Merck Frosst Canada & Co. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
CA2527773A1 (en) * 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines as dp receptor antagonists
US20080153817A1 (en) * 2003-08-07 2008-06-26 Dirk Beher Treatment for Alzheimer's Disease and Related Conditions
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
KR20070033033A (ko) 2004-07-16 2007-03-23 프로테오시스 악티엔게젤샤프트 염증성 질환 치료제로서 ｐａｒｐ 및 ｓｉｒ 조절 활성을갖는 무스카린 길항제
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CN101160125A (zh) * 2005-04-13 2008-04-09 默克公司 烟酸受体激动剂、含有这样化合物的组合物和治疗方法
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
KR20190004843A (ko) * 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010081823A1 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as otoprotective agent
WO2011051151A1 (de) 2009-10-26 2011-05-05 Bayer Cropscience Ag Neue feste form von 4-[[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5h)-on
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
US9797903B2 (en) 2012-10-24 2017-10-24 Winthrop-University Hospital Non-invasive biomarker to identify subject at risk of preterm delivery
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
US20180021302A1 (en) * 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
WO2019055661A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS
US11279656B2 (en) * 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN115260173A (zh) * 2021-04-30 2022-11-01 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) * 2023-07-10 2023-10-10 青岛科技大学 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
EP0234708B1 (en) 1986-01-23 1991-02-27 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
ATE337294T1 (de) * 1995-06-21 2006-09-15 Shionogi & Co Bizyklische aminoderivate und enthaltende pgd2- antagonisten
IL130660A (en) * 1996-12-13 2002-03-10 Shionogi & Co History of benzothiophenecarboxamide and PGD2 antibodies containing them
DE69925270T2 (de) * 1998-06-03 2006-02-23 Shionogi & Co., Ltd. Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten

Also Published As

Publication number Publication date
ATE284388T1 (de) 2004-12-15
AU2001277430B2 (en) 2006-05-25
HRP20021039B1 (hr) 2011-03-31
BR0112756A (pt) 2003-06-24
WO2002008186A3 (en) 2002-03-21
NO325011B1 (no) 2008-01-14
EA006765B1 (ru) 2006-04-28
DE60107687T2 (de) 2005-12-01
HUP0301745A3 (en) 2010-03-29
HK1058934A1 (en) 2004-06-11
EE05287B1 (et) 2010-04-15
EP1305286B1 (en) 2004-12-08
CN1443165A (zh) 2003-09-17
JP4119745B2 (ja) 2008-07-16
IL153406A0 (en) 2003-07-06
CA2416867C (en) 2008-03-25
BG66084B1 (bg) 2011-03-31
CZ2003236A3 (cs) 2003-05-14
EA200300171A1 (ru) 2003-06-26
RS50491B (sr) 2010-03-02
SK287507B6 (sk) 2010-12-07
ZA200300554B (en) 2004-04-23
WO2002008186A2 (en) 2002-01-31
PL207342B1 (pl) 2010-12-31
IS6655A (is) 2002-12-12
AU7743001A (en) 2002-02-05
BG107438A (bg) 2003-09-30
KR20030024810A (ko) 2003-03-26
YU97902A (sh) 2006-05-25
IS2170B (is) 2006-11-15
HUP0301745A2 (hu) 2003-09-29
CN1214007C (zh) 2005-08-10
DE60107687D1 (de) 2005-01-13
NO20030374L (no) 2003-01-24
ES2231526T3 (es) 2005-05-16
UA73787C2 (en) 2005-09-15
PT1305286E (pt) 2005-04-29
CA2416867A1 (en) 2002-01-31
ECSP034428A (es) 2003-03-10
SK932003A3 (en) 2003-06-03
JP2004504380A (ja) 2004-02-12
DZ3402A1 (fr) 2002-01-31
EP1305286A2 (en) 2003-05-02
GEP20053595B (en) 2005-08-10
PL363168A1 (en) 2004-11-15
HRP20021039A2 (en) 2004-10-31
US6410583B1 (en) 2002-06-25
IL153406A (en) 2008-03-20
KR100746814B1 (ko) 2007-08-06
MXPA03000710A (es) 2003-06-04
EE200300033A (et) 2004-10-15
NZ523106A (en) 2005-01-28
NO20030374D0 (no) 2003-01-24

Similar Documents

Publication Publication Date Title
DK1305286T3 (da) Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
NO20032831D0 (no) Pyrimidinaminer som angiogenese-modulatorer
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
NO20014986L (no) 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης